Holen Sie sich die Stockscreener-App
34.38
3.55%
1.18
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$33.20
Offen:
$32.64
24-Stunden-Volumen:
1.60M
Relative Volume:
0.79
Marktkapitalisierung:
$3.86B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-6.5361
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
+6.44%
1M Leistung:
+12.32%
6M Leistung:
-29.33%
1J Leistung:
-34.78%
1-Tages-Spanne:
$32.64
$34.41
1-Wochen-Bereich:
$32.30
$34.62
52-Wochen-Spanne:
$29.31
$61.38
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
34.38 | 3.86B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsCYTK - ACCESS Newswire
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan - Yahoo Finance
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program | CYTK Stock News - GuruFocus
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program - The Manila Times
JP Morgan Lowers Price Target for Cytokinetics (CYTK) to $53 | C - GuruFocus
Cytokinetics (CYTK) Target Price Cut by JPMorgan Analyst | CYTK Stock News - GuruFocus
CYTK ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress - mx.advfn.com
Shareholders That Lost Money on Cytokinetics, Incorporated(CYTK) Should Contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Insider Sell Alert: Kaye Edward M. MD Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Cytokinetics at Jefferies Conference: Aficamten’s Market Expansion By Investing.com - Investing.com Nigeria
Cytokinetics at Jefferies Conference: Aficamten’s Market Expansion - Investing.com India
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cetera Investment Advisers Decreases Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Cytokinetics (NASDAQ:CYTK) Given New $84.00 Price Target at Mizuho - Defense World
Recognizing Hypertrophic Cardiomyopathy in Women: Addressing Misdiagnosis - HCPLive
Cytokinetics (CYTK) Stock Update: Mizuho Lowers Price Target | C - GuruFocus
Cytokinetics (CYTK) Gets Price Target Reduction from Mizuho Anal - GuruFocus
Cytokinetics to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Cytokinetics Management Reveals Latest Updates at Jefferies Healthcare ConferenceLive Webcast Available - Stock Titan
Cytokinetics (CYTK) Stock Update: Mizuho Lowers Price Target | CYTK Stock News - GuruFocus
Mizuho Cuts Price Target on Cytokinetics to $84 From $103, Keeps Outperform Rating - marketscreener.com
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape - Investing.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
Cytokinetics at RBC Conference: Strategic Insights on Drug Development By Investing.com - Investing.com Canada
Protect Your Investment: Contact Levi & Korsinsky About the Cytokinetics, Incorporated (CYTK) Investigation - ACCESS Newswire
BNP Paribas Financial Markets Trims Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Cytokinetics (CYTK) Showcases Promising Aficamten Data for HCM T - GuruFocus
Cytokinetics (CYTK) Showcases Promising Aficamten Data for HCM Treatment | CYTK Stock News - GuruFocus
Cytokinetics Presents Additional Data Related to Aficamten at th - GuruFocus
Cytokinetics Announces SEQUOIA-HCM Analysis Results Highlighting Aficamten's Efficacy and Disparities in Hypertrophic Cardiomyopathy Outcomes Across Patient Demographics - Nasdaq
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Ru - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance
Cytokinetics (NASDAQ:CYTK) Upgraded at Cantor Fitzgerald - Defense World
Cytokinetics (NASDAQ:CYTK) Earns Buy Rating from Needham & Company LLC - Defense World
Insider Sell: Muna Bhanji Sells 1,454 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics to Host Symposium on Contemporary Landscapes in Mus - GuruFocus
Cytokinetics (CYTK) to Host Muscle Biology Symposium in 2025 | C - GuruFocus
Cytokinetics (CYTK) to Host Muscle Biology Symposium in 2025 | CYTK Stock News - GuruFocus
Exclusive Muscle Biology Summit: Genentech, Stanford, and Penn Leaders Join Cytokinetics Research Symposium - Stock Titan
Bluebird extends deal deadline; Affimed files for insolvency - BioPharma Dive
Needham Reiterates Buy Rating on Cytokinetics (CYTK) with $72 Price Target | CYTK Stock News - GuruFocus
Cytokinetics builds its best-in-class case for aficamten - biocentury.com
Cytokinetics (CYTK) Rallies as Phase 3 Trial Succeeds for Lead D - GuruFocus
Stifel maintains confidence in Cytokinetics stock post-trial success By Investing.com - Investing.com Canada
Cytokinetics Unusual Options Activity - Nasdaq
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):